| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.047 | 0.5 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.12 | 0.5 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |